A Retrospective Observational Study on the Effects of Probiotics on HBsAg Clearance
NCT ID: NCT06313255
Last Updated: 2024-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
40 participants
OBSERVATIONAL
2023-05-09
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Are the probiotics have an effect in promoting HBV clearance? The participants will observe the HBV clearance rate in chronic hepatitis B patients receive probiotics in addition to the routine antiviral therapy.
Researchers will compare the HBV clearance rate in chronic hepatitis B patients receive probiotics and antiviral therapy with those receiving solely antiviral therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Probiotics on Gut Microbiota During the Helicobacter Pylori Eradication
NCT05662514
Probiotics in PBC Patients of Poor Response to UDCA
NCT03521297
Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
NCT01501162
Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH
NCT04555434
Metabolomic Effects of Probiotics Administration
NCT04506385
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PegIFNα2b
PegIFNα2b
The patients receive PegIFNα2b therapy
PegIFNα2b+probiotics
PegIFNα2b+probiotics
The patients receive both PegIFNα2b and probiotics therapy
Nucleoside analog
Nucleoside analog
The patients receive nucleoside analog therapy
Nucleoside analog+probiotics
Nucleoside analog+probiotics
The patients receive both nucleoside analog and probiotics therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PegIFNα2b
The patients receive PegIFNα2b therapy
PegIFNα2b+probiotics
The patients receive both PegIFNα2b and probiotics therapy
Nucleoside analog
The patients receive nucleoside analog therapy
Nucleoside analog+probiotics
The patients receive both nucleoside analog and probiotics therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients with other liver diseases
* pregnancy patients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qilu Hospital of Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qilu Hospital of Shandong University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KYLL-202301-008-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.